Zika Virus: Where Is the Treatment?

Mumtaz, Noreen; Kampen, Jeroen J. A. van; Reusken, Chantal; Boucher, Charles A.

doi:10.1007/s40506-016-0083-7

Cited by 19 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current approaches to mitigate the impact of ZIKV infection, especially during pregnancy, include reducing exposure to mosquito vectors (45)(46)(47) and developing vaccines, antivirals, and antibody therapies that can be administered either prophylactically or therapeutically to attenuate disease (7,(48)(49)(50). The contribution of placental immune responses to ZIKV has been largely ignored.…”

Section: Discussionmentioning

confidence: 99%

“…All procedures for handling ZIKV were approved by the Institutional Biosafety Committee. Stocks of ZIKV were generated by infecting Vero cells at an MOI of 0.01 50% tissue culture infectious doses (TCID 50 ) per cell in DMEM supplemented with 2.5% FBS, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM l-glutamine (infection media [IM]). Approximately 72 hpi, the infected cell supernatant fluids were collected, clarified by centrifugation at 900 g for 10 minutes, and stored in aliquots at -80°C.…”

Section: Methodsmentioning

confidence: 99%

“…Small or discolored fetuses or the absence of a fetus at an implantation site were counted as nonviable. Maternal spleens, placentas, and fetuses were collected from each dam for determination of viral burden by quantitative RT-PCR (qRT-PCR), TCID 50 assay, and IHC. All animal studies were conducted under animal biosafety level 2 (BSL2) containment.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection

et al. 2019

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection

et al. 2019

View full text Add to dashboard Cite

“…Recent studies revealed that ZIKV was found to be sensitive to the antiviral effects of type 1 and type 2 IFNs ( Fellner, 2016 ). Anti-viral nucleoside analogs GS-5734 and BCX4430 are currently in the first and second phases of clinical trials ( Mumtaz et al, 2016 ). Further, recent studies showed that ZIKV infection could act in response to IFN therapy ( Hamel et al, 2015 ).…”

Section: Recent Advancementsmentioning

confidence: 99%

“…Initially, 7DMA and 2CMC were developed for the treatment of hepatitis C which is distantly linked to ZIKV. Studies have shown that these compounds have antiviral activities against other flavivirus ( Mumtaz et al, 2016 ). Brazil’s Butantan Institute, Sao Paulo was the first group to announce the development of ZIKV vaccine ( Fellner, 2016 ).…”

Section: Recent Advancementsmentioning

confidence: 99%

Recent Perspectives on Genome, Transmission, Clinical Manifestation, Diagnosis, Therapeutic Strategies, Vaccine Developments, and Challenges of Zika Virus Research

2017

View full text Add to dashboard Cite

One of the potential threats to public health microbiology in 21st century is the increased mortality rate caused by Zika virus (ZIKV), a mosquito-borne flavivirus. The severity of ZIKV infection urged World Health Organization (WHO) to declare this virus as a global concern. The limited knowledge on the structure, virulent factors, and replication mechanism of the virus posed as hindrance for vaccine development. Several vector and non-vector-borne mode of transmission are observed for spreading the disease. The similarities of the virus with other flaviviruses such as dengue and West Nile virus are worrisome; hence, there is high scope to undertake ZIKV research that probably provide insight for novel therapeutic intervention. Thus, this review focuses on the recent aspect of ZIKV research which includes the outbreak, genome structure, multiplication and propagation of the virus, current animal models, clinical manifestations, available treatment options (probable vaccines and therapeutics), and the recent advancements in computational drug discovery pipelines, challenges and limitation to undertake ZIKV research. The review suggests that the infection due to ZIKV became one of the universal concerns and an interdisciplinary environment of in vitro cellular assays, genomics, proteomics, and computational biology approaches probably contribute insights for screening of novel molecular targets for drug design. The review tried to provide cutting edge knowledge in ZIKV research with future insights required for the development of novel therapeutic remedies to curtail ZIKV infection.

show abstract

Favipiravir (6‐Fluoro‐3‐hydroxy‐2‐pyrazinecarboxamide) a Broad Spectrum Inhibitor of Viral RNA Polymerase in COVID‐19 Treatment

2021

View full text Add to dashboard Cite

A pandemic disease, COVID‐19, affecting over 253 million and 5.1 million deaths reported as on November 2021 from across the globe. The worst hit pandemic since a century. Scientists around the world are working towards the development of drugs for its treatment. Several existing antiviral medications have been tried for the same. Among these, Favipiravir, a broad‐spectrum antiviral drug originally developed to treat influenza, shows noted activity against an ample range of RNA viruses. It is an oral antiviral drug with good bioavailability found to be effective in the treatment of COVID‐19. This drug has acquired FDA manifestation for drug‐resistant Influenza as it has confirmed its safety profile. There has been growing evidence that it helps in early viral clearance and speedy symptomatic relief against COVID‐19. This review attempts to provide synthetic methods of favipiravir, mechanism of action and its importance in the treatment of COVID‐19 and other viruses.

show abstract

Zika Virus: Where Is the Treatment?

Cited by 19 publications

References 0 publications

IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection

IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection

Recent Perspectives on Genome, Transmission, Clinical Manifestation, Diagnosis, Therapeutic Strategies, Vaccine Developments, and Challenges of Zika Virus Research

Favipiravir (6‐Fluoro‐3‐hydroxy‐2‐pyrazinecarboxamide) a Broad Spectrum Inhibitor of Viral RNA Polymerase in COVID‐19 Treatment

Contact Info

Product

Resources

About